RT @_afao: The flatter curve and a slower infection rate means a less stressed health care system, fewer hospital visits on any given day a…
ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Managing HIV / HepC; Sofosbuvir / Velpatasvir effective with management well suited to primary care settings.
Doyle,J (session presentation) ; coEC Study
Lu,Y (2 poster presentations) ; ASTRAL-5 Study
This presentation by J Doyle from the Burnet Institute highlighted the findings from the first year of the co-EC study in Melbourne. Modelling presented by Scott, et al at EASL 2017, proposes that treatment of 515 co-infected individuals in Victoria will reduce the prevalence of hepatitis C within the GBM community by 80%.
In the first year clinical data was collected on 160 chronic HIV/HepC co-infected individuals on ART. This included biochemical, haematological and fibrosis data. Primary care clinicians assessed this data and individuals either:
- received immediate DAA therapy (40%)
- received DAA therapy after specialist advice (31%)
- were referred for specialist care (19%)
Referrals were predominantly required for known cirrhosis, APRI score >1, malignancy, renal/cardiac disease or fibroscan >12.5Kp.
This study highlighted the capacity for the majority of non-cirrhotic HIV/Hepatitis C individuals to be effectively managed by a primary care clinical team. This model of care fits comfortably with Australia's move toward patient centred, community based care within health care homes.
ASTRAL-5 (2 poster presentations)
The efficacy, tolerability and safety of Sofosbuvir / Velpatasavir in HIV / Hep C co-infection was presented. 106 patients were enrolled for 12 weeks of SOF/VEL therapy. SVR at 12 weeks was demonstrated in the majority of patients across the 5 genotypical variants assessed.
ASTRAL-5: SVR12 rates by genotype.
- Genotype SVR12% (n/N)
- Total 95%
- GT1a 95%
- GT1b 92%
- GT2 100%
- GT3 92%
- GT4 100%
No patient experienced HIV virological rebound.
Side effects were similar to other available DAAs with fatigue (25%), headache (13%) and nausea (7%) reported.
- Drug-Drug interaction studies demonstrated no clinically significant interaction with a wide range of commonly used ART regimes. The only exception is that of EFV. There was a 53% reduction in VEL levels and thus EFV is currently not recommended for use with Velpatasvir.
These presentations highlighted the suitability of primary care teams to effectively manage HIV/Hep C co-infection. This community based, patient centric model of care will enhance our capacity to eliminate Hepatitis C among the HIV cohort within Australia. The combination of Sofosbuvir with Velpatasvir provides pan-genotypical efficacy, good tolerability and limited drug interaction with ART. These characteristics will further enhance the ability of HIV/HepC to be safely and effectively managed in primary care settings within Australia.